
Currently out of the existing stock ratings of Tim Lugo, 35 are a BUY (79.55%), 9 are a HOLD (20.45%).
Analyst Tim Lugo, currently employed at WILLIAM BLAIR, has had 56.06% of price targets met with an average potential upside of 48.08%, reached in 692 days on average.
Tim Lugo has documented 73 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BMRN, Biomarin Pharmaceutical at 30-Oct-2024.
Analyst best performing recommendations are on ALLK (ALLAKOS).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) on 3/20/2013. The price target of $52 was fulfilled within 198 days with a profit of $19.23 (58.68%), with a performance score of 2.96.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 23-Jun-2025
$20
$-0.11 (-0.55%)
$16
4 months 10 days ago
(09-Jul-2026)
7/17 (41.18%)
$-0.52 (-2.53%)
71
Sell Since 24-Jul-2025
$13
$-3.85 (-22.85%)
7 months 24 days ago
(26-Mar-2026)
0/2 (0%)
$-8.68 (-40.04%)
Sell Since 22-Jul-2025
7 months 24 days ago
(26-Mar-2026)
14/35 (40%)
$28.03 (127.58%)
364
Buy Since 19-Mar-2026
$37
$20.15 (119.58%)
$50
8 months ago
(19-Mar-2026)
0/16 (0%)
$20.35 (122.22%)
Buy Since 13-Mar-2026
$31
$14.15 (83.98%)
$19
8 months 6 days ago
(13-Mar-2026)
4/14 (28.57%)
$14.6 (89.02%)
322
What Year was the first public recommendation made by Tim Lugo?